The DOI matches its Crossref record; 183 of the 184 references it cites were found in a registry or an index.
Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives
Abstract
Hyperprolactinemia is increasingly studied as a frequent and potentially important consequence of antipsychotic medication treatment. Some individuals presenting with hyperprolactinemia remain asymptomatic, but others may exhibit a wide range of clinical symptoms resulting from either the direct effects of prolactin on body tissues (galactorrhea, gynecomastia) or endocrine-related secondary effects (sexual and reproductive dysfunction in the short term, and possibly the risk of tumorigenesis and osteoporosis in the longer term). Short-term side effects may negatively impact medication compliance, and long-term effects have the potential for serious health consequences. Antipsychotic medications have differing propensities to cause prolactin elevation. The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. A comprehensive overview of antipsychotics and hyperprolactinemia is presented together with a review of emerging evidence about the short- and long-term health risks of hyperprolactinemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although it has been suggested that raised prolactin levels provoked by AP medication can lead to an increased risk of osteoporosis in patients with schizophrenia (471, 487), clinical data implicating AP-induced hyperprolactinemia as a possible major risk factor for bone loss are limited and contradictory (488,489).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [488]
In the citing paper
“Nevertheless, the available data seem to indicate that hyperprolactinemia with associated hypogonadism may be a risk factor (488), leading to bone mineral loss in women as well as men (499).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [488]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Bôle-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. (1998) · Endocrine reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,973
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R., Graffeo, K. A., & Thieme, M. E. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 801
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777
Trân, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. M., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 712
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Hip Fracture and the Use of Estrogens in Postmenopausal Women
Kiel, D. P., Felson, D. T., Anderson, J. J., Wilson, P. W. F., & Moskowitz, M. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711053171901 · Cited by 634
Hip Fracture and the Use of Estrogens in Postmenopausal Women
Kiel, D. P., Felson, D. T., Anderson, J. J., Wilson, P. W. F., & Moskowitz, M. A. (1988) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198807000-00018 · Cited by 625
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., ZIMBROFF, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M. W., Stock, E. G., Stringfellow, J., Ingenito, G. G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 592
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 590
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 585
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Peuskens, J. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
Predictors of Noncompliance in Patients With Schizophrenia
Perkins, D. O. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1206 · Cited by 546
Efficacy of Olanzapine in Acute Bipolar Mania A Double-blind, Placebo-Controlled Study
Tohen, M. F. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501
Quetiapine in Patients With Schizophrenia
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 482
Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 471
Marder, S. R., McQuade, R. D., Stock, E. G., Kaplita, S., Marcus, R. N., Safferman, A. Z., Saha, A. R., Ali, M. W., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1146 · Cited by 424
Prolactin: The New Biology of an Old Hormone
Goffin, V., Binart, N., Touraine, P. A., & Kelly, P. A. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.081501.131049 · Cited by 416
Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
Correll, C. U., & Carlson, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 406
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
DeLeon, A., Patel, N. C., & Crismon, M. L. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 364
Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00127-0 · Cited by 350
Conley, R. R., & Mahmoud, R. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 336
The Texas Implementation of Medication Algorithms
Suppes, T. M., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 327
Self-citationKasper, S. F., Lerman, M. N., McQuade, R. D., Saha, A. R., Carson, W. H., Ali, M. W., Archibald, D., Ingenito, G. G., Marcus, R. N., & Pigott, T. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Prolactin Levels and Adverse Events in Patients Treated with Risperidone
Kleinberg, D. L., Davis, J. M., Coster, R. D., van Baelen, B., & Brecher, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00011 · Cited by 307
Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women
Hankinson, S. E., Willett, W. C., Michaud, D. S., Manson, J. E., Colditz, G. A., Longcope, C., ROSNER, B. A., & Speizer, F. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.629 · Cited by 295
Hirschfeld, R. M. A., Keck, P. E., Kramer, M., Karcher, K., Canuso, C., Eerdekens, M., & Grossman, F. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1057 · Cited by 273
Lambert, M., Conus, P., Eide, P., Mass, R., Karow, A., Moritz, S., Golks, D., & Naber, D. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.06.031 · Cited by 268
ICI 204,636, an Atypical Antipsychotic
Borison, R. L., Arvanitis, L. A., & Milier, B. G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00008 · Cited by 265
Olanzapine Versus Divalproex in the Treatment of Acute Mania
Tohen, M. F., Baker, R. W., Altshuler, L. L., Zarate, C. A., Suppes, T. M., Ketter, T. A., Milton, D. R., Risser, R. C., Gilmore, J. A., Breier, A. F., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1011 · Cited by 256
Self-citationSexual dysfunction in patients taking conventional antipsychotic medication
Smith, S., O'Keane, V., & Murray, R. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.1.49 · Cited by 256
Medication-Induced Hyperprolactinemia
Molitch, M. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1050 · Cited by 251
Osteoporosis in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., NEER, R. M., Ridgway, E. C., & KLIBANSKI, A. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-777 · Cited by 249
Yatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
David, S. R., Taylor, C. C., Kinon, B. J., & Breier, A. F. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80086-7 · Cited by 236
Sexual Dysfunction and Plasma Prolactin Levels in Neuroleptic-treated Schizophrenic Outpatients
GHADIRIAN, A. M., Chouinard, G., & Annable, L. (1982) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198208000-00004 · Cited by 225
Meaney, A. M., Smith, S., Howes, O. D., O'Brien, M., Murray, R. M., & O'Keane, V. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.6.503 · Cited by 217
Bobes, J., A-PORTILLA, M. P. G., Rejas, J., ndez, G. H., García-García, M., Rico‐Villademoros, F., & PORRAS, A. (2003) · Journal of Sex & Marital Therapy · doi:10.1080/713847170 · Cited by 213
Breier, A. F., Malhotra, A. K., Su, T., Pinals, D. A., Elman, I., Adler, C. M., Lafargue, R. T., Clifton, A. D., & Pickar, D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.294 · Cited by 207
The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis
Smith, S. M., Wheeler, M. J., Murray, R. M., & O’Keane, V. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00002 · Cited by 202
Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201
Dopamine Antagonists and the Development of Breast Cancer
Wang, P. S., Walker, A. M., Tsuang, M. T., Orav, E. J., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1147 · Cited by 196
What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?
Knegtering, H., van der Moolen, A. E. G. M., Castelein, S., Kluiter, H., & van den Bosch, R. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00130-0 · Cited by 196
Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002) · Pediatrics · doi:10.1542/peds.110.3.e34 · Cited by 195
Decreased Bone Mineral Density in Medicated Psychiatric Patients
Halbreich, U. M., Rojansky, N., Palter, S. F., Hreshchyshyn, M. M., Kreeger, J., Bakhai, Y., & Rosan, R. C. (1995) · Psychosomatic Medicine · doi:10.1097/00006842-199509000-00011 · Cited by 193
Importance of Gonadal Steroids to Bone Mass in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., Oppenheim, D. S., & Klibanski, A. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-526 · Cited by 190
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.133 · Cited by 189
Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.007 · Cited by 187
Risperidone in the treatment of acute mania
Khanna, S., Vieta, E., Lyons, B., Grossman, F., Eerdekens, M., & Kramer, M. L. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.3.229 · Cited by 187
Crawford, A. M., Beasley, C. M., & Tollefson, G. D. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00036-4 · Cited by 185
GOFF, D. C., Posever, T. A., Herz, L. R., Simmons, J., Kletti, N., Lapierre, K. A., Wilner, K. D., Law, C., & Ko, G. N. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00009 · Cited by 183
Arató, M., Connor, R. O., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178
Effect of clozapine on human serum prolactin levels
Meltzer, H. Y., Goode, D. J., Schyve, P. M., Young, M. A., & Fang, V. S. (1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.12.1550 · Cited by 171
Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania
Vieta, E., Bourin, M., Sanchez, R., Marcus, R. N., Stock, E. G., McQuade, R. D., Carson, W. H., Abou-Gharbia, N., Swanink, R., & Iwamoto, T. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.3.235 · Cited by 171
Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences
Wieck, A., & Haddad, P. M. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.182.3.199 · Cited by 167
Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., & The Risperidone Disruptive Behavior Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.677 · Cited by 161
Effects of Psychiatric Disorders and Psychotropic Medications on Prolactin and Bone Metabolism
Misra, M., Papakostas, G. I., & Klibanski, A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1205 · Cited by 156 · cited 1×
“Direct effects on the breast and sexual dysfunction may occur in both sexes.(3,16) Galactorrhea Available data suggest that galactorrhea (the abnormal discharge of milk from the breast) associated with elevated prolactin is much more prevalent in women than men.”
BackgroundThe WHI Estrogen-Alone Trial—Do Things Look Any Better?
Hulley, S. B. (2004) · JAMA · doi:10.1001/jama.291.14.1769 · Cited by 156
Male Sexual Dysfunction and Quality of Life in Schizophrenia
Olfson, M., Uttaro, T., Carson, W. H., & Tafesse, E. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0309 · Cited by 154 · cited 1×
“Understanding the relationship between antipsychotic-induced hyperprolactinemia and sexual side effects is important when prescribing antipsychotic treatments.(35) Studies relating hyperprolactinemia with sexual dysfunction are summarized in Table 3 and have been organized according to the presence or lack of correlat…”
BackgroundCircadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia
Rao, M. L., Gross, G., Strebel, B., Halaris, A., Huber, G., Bräunig, P., & Marler, M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91147-9 · Cited by 154
Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels
Knegtering, R., Baselmans, P., Castelein, S., Bosker, F. J., Bruggeman, R., & van den Bosch, R. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1010 · Cited by 150
A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning
Knegtering, R., Castelein, S., Bous, H., van der Linde, J., Bruggeman, R., Kluiter, H., & van den Bosch, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106220.36344.04 · Cited by 147
D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
Gefvert, O., Lundberg, T., Wieselgren, I., Bergström, M., Långström, B., Wiesel, F., & Lindström, L. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00133-4 · Cited by 145
Copolov, D., Link, C. G. G., & Kowalcyk, B. B. (2000) · Psychological Medicine · doi:10.1017/s0033291799001476 · Cited by 144
Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study
Szarfman, A., Tonning, J. M., Levine, J. G., & Doraiswamy, P. M. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.748 · Cited by 144
Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea
Biller, B. M. K., Baum, H. B. A., Rosenthal, D. I., SAXE, V. C., Charpie, P. M., & Klibanski, A. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.3.1517356 · Cited by 143
Croonenberghs, J., Fegert, J. M., Findling, R. L., Smedt, G. D., & Dongen, S. V. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000145805.24274.09 · Cited by 135
Elevated Prolactin in Pediatric Patients on Typical and Atypical Antipsychotics
Wudarsky, M., Nicolson, R., Hamburger, S. D., Spechler, L., Gochman, P., Bedwell, J. S., Lenane, M., & RAPOPORT, J. L. (1999) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1999.9.239 · Cited by 133
Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130
Sexual Disturbances During Clozapine and Haloperidol Treatment for Schizophrenia
Hummer, M., Kemmler, G., Kurz, M., Kurzthaler, I., OBERBAUER, H., & Fleischhacker, W. W. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.631 · Cited by 126
y Revuelta, J. L. G. D. R., Lal, S., Ettigi, P. G., Hontela, S., Müller, H., & Friesen, H. G. (1976) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1976.tb01953.x · Cited by 125
The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., Lieberman, J. A., & Schooler, N. R. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006926 · Cited by 125
Antipsychotics: impact on prolactin levels
Goodnick, P. J., Santana, O., & Rodriguez, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.10.1381 · Cited by 124
Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone
Weiden, P. J., Daniel, D. G., Simpson, G. M., & Romano, S. J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095347.32154.08 · Cited by 124
An Open-Label Trial of Risperidone in Children and Adolescents with Bipolar Disorder
Biederman, J., Mick, E. O., Wozniak, J. R., Aleardi, M., Spencer, T. J., & Faraone, S. V. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.311 · Cited by 124
Subjective utility ratings of neuroleptics in treating schizophrenia
Finn, S. E., Bailey, J. M., Schultz, R. T., & Faber, R. A. (1990) · Psychological Medicine · doi:10.1017/s0033291700036539 · Cited by 120
Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.
Maguire, G. A. (2002) · PubMed · Cited by 119
Accelerated Osteoporosis in Psychiatric Patients: Possible Pathophysiological Processes
Halbreich, U. M., & Palter, S. F. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.447 · Cited by 119
Use of antipsychotics in children and adolescents.
Findling, R. L., Steiner, H., & Weller, E. B. (2005) · PubMed · Cited by 118
Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents
Naidoo, U., Goff, D. C., & Klibanski, A. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00129-4 · Cited by 113
Becker, D., Liver, O., Mester, R., Rapoport, M., Weizman, A., & Weiss, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0704 · Cited by 107
Dossenbach, M., Hodge, A., Anders, M., Molnár, B., Peciukaitiene, D., Krupka-Matuszczyk, I., Tatu, M., Bondar, V., Pecenak, J., Gorjanc, T., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704005012 · Cited by 106
Forearm and Vertebral Bone Mineral in Treated and Untreated Hyperprolactinemic Amenorrhea*
Schlechte, J., El-Khoury, G. Y., Kathol, M. H., & Walkner, L. M. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-1021 · Cited by 105
Kim, K., Pae, C., Chae, J., Bahk, W., Jun, T.-Y., Kim, D., & Dickson, R. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0506 · Cited by 104
Emsley, R. A., Turner, H. J., Schronen, J., Botha, K., Smit, R., & Oosthuizen, P. P. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0516 · Cited by 104
Guille, C., Sachs, G. S., & Ghaemi, S. N. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0907 · Cited by 103
An Update of Fast-Off Dopamine D2 Atypical Antipsychotics
Seeman, P. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1984-a · Cited by 102
Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone
Davis, G. C., Buchsbaum, M. S., van Kammen, D. P., & Bunney, W. E. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90029-5 · Cited by 101
Barzman, D. H., DelBello, M. P., Kowatch, R. A., Gernert, B., Fleck, D. E., Pathak, S., Rappaport, K., Delgado, S. V., Campbell, P., & Strakowski, S. M. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.593 · Cited by 100
Melkersson, K. I., Hulting, A., & Rane, A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01352.x · Cited by 99
Melkersson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0614 · Cited by 98
Kinon, B., AHL, J. S. B., Liu‐Seifert, H., & Maguire, G. A. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.12.006 · Cited by 94
Vertebral Body Bone Mineral Content in Hyperprolactinemic Women
KOPPELMAN, M. C. S., Kurtz, D., Morrish, K. A., Bou, E., SUSSER, J. K., Shapiro, J. R., & Loriaux, D. L. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-6-1050 · Cited by 93
Atypical antipsychotics: newer options for mania and maintenance therapy
Vieta, E., & Goikolea, J. M. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00212.x · Cited by 89
Bj�rndal, N., Bjerre, M. T., Gerlach, J., Kristjansen, P., Magelund, G., Oestrich, I. H., & W�hrens, J. (1980) · Psychopharmacology · doi:10.1007/bf00427590 · Cited by 85
Miceli, J. J., Wilner, K. D., Hansen, R., Johnson, A., Apseloff, G., & Gerber, N. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00147.x · Cited by 82
Abraham, G., Paing, W. W., Kaminski, J., Joseph, A., Kohegyi, E., & Josiassen, R. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1618 · Cited by 82
Serotonergic regulation of renin and prolactin secretion
de Kar, L. D. V., Rittenhouse, P. A., Li, Q., & Levy, A. D. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00097-6 · Cited by 81
A STUDY OF SERUM PROLACTIN LEVELS IN SCHIZOPHRENIA: COMPARISON OF MALES AND FEMALES
Kuruvilla, A., Peedicayil, J., Srikrishna, G., Kuruvilla, K., & Kanagasabapathy, A. S. (1992) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1992.tb00511.x · Cited by 81
Hyperprolactinemia and Schizophrenia: Mechanisms and Clinical Aspects
Halbreich, U. M., & Kahn, L. S. (2003) · Journal of Psychiatric Practice · doi:10.1097/00131746-200309000-00003 · Cited by 79
Tandon, R., & Halbreich, U. M. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00109-9 · Cited by 76
Aripiprazole in the Treatment of Pediatric Bipolar Disorder: A Systematic Chart Review
Biederman, J., McDonnell, M. A., Wozniak, J. R., Spencer, T. J., Aleardi, M., Falzone, R., & Mick, E. O. (2005) · CNS Spectrums · doi:10.1017/s1092852900019489 · Cited by 75
Addington, D. E., Pantelis, C., Dineen, M., Benattia, I., & Romano, S. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1207 · Cited by 75
Alfaro, C. L., Wudarsky, M., Nicolson, R., Gochman, P., Sporn, A. L., Lenane, M., & Rapoport, J. L. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602760219126 · Cited by 73
Mullen, B., Brar, J. S., Vagnucci, A. H., & Ganguli, R. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00061-x · Cited by 73
Strategies for Switching From Conventional Antipsychotic Drugs or Risperidone to Olanzapine
Kinon, B. J., Basson, B. R., Gilmore, J. A., Malcolm, S. K., & Stauffer, V. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1105 · Cited by 70
Saito, E., Correll, C. U., Gallelli, K. A., McMeniman, M., Parikh, U. H., Malhotra, A. K., & Kafantaris, V. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.350 · Cited by 70
A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia
King, D. J., Link, C. G. G., & Kowalcyk, B. B. (1998) · Psychopharmacology · doi:10.1007/s002130050603 · Cited by 70
Windgassen, K., Wesselmann, U., & Mönking, S. (2008) · Neuropsychobiology · doi:10.1159/000119265 · Cited by 67
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
Kane, J. M., Khanna, S., Rajadhyaksha, S., & Giller, E. L. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182114.65134.81 · Cited by 65
Howes, O. D., Wheeler, M. J., Meaney, A.-M., O'Keane, V., Fogelman, I., Blake, G., Murray, R. M., & Smith, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162798.87249.4d · Cited by 64
Buckley, P. F. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004510 · Cited by 63
Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia
Ataya, K. M., Mercado, A., Kartaginer, J., Abbasi, A., & Moghissi, K. S. (1988) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60365-5 · Cited by 60
Riedel, M. J., Müller, N., Strassnig, M., Spellmann, I., Engel, R. R., Musil, R., Dehning, S., Douhet, A., Schwarz, M., & Möller, H. ‐. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0622-6 · Cited by 59
Relation of Plasma Prolactin to Clinical Response in Schizophrenic Patients
GRUEN, P. H. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770340072008 · Cited by 58
Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response
Meltzer, H. Y., Busch, D. A., & Fang, V. S. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90001-x · Cited by 54
Fujimoto, V. Y., Clifton, D. K., Cohen, N. L., & Soules, M. R. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90375-f · Cited by 54
Markianos, M., Hatzimanolis, J., & Lykouras, L. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00040-1 · Cited by 53
Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636).
Hamner, M. B., Arvanitis, L. A., Miller, B. G., Link, C. G. G., & Hong, W. W. (1996) · PubMed · Cited by 51
The 24-Hour Profile of Plasma Prolactin in Men With Major Endogenous Depressive Illness
Linkowski, P., Cauter, E. V., L’Hermite‐Balériaux, M., Kerkhofs, M., Hubain, P., L'Hermite, M., & Mendlewicz, J. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810090055009 · Cited by 50
Ziprasidone, a New Atypical Antipsychotic Drug
Carnahan, R. M., Lund, B. C., & Perry, P. J. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.7.717.34575 · Cited by 50
Haloperidol plasma levels and clinical response in paranoid schizophrenics
Linkowski, P., Hubain, P., von Frenckell, R., & Mendlewicz, J. (1984) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00381354 · Cited by 50
An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction
Byerly, M., Lescouflair, E., Weber, M., Bugno, R., FISHER, R., Carmody, T. J., Varghese, F. P., & Rush, A. J. (2004) · Journal of Sex & Marital Therapy · doi:10.1080/00926230490465082 · Cited by 49
Self-citationTolerability Profile of Atypical Antipsychotics in Children and Adolescents
Stigler, K. A., Potenza, M. N., & McDougle, C. J. (2001) · Pediatric Drugs · doi:10.2165/00128072-200103120-00005 · Cited by 48
The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations
Rubín, R. T., & Hays, S. E. (1980) · Psychoneuroendocrinology · doi:10.1016/0306-4530(80)90015-3 · Cited by 45
Reversal of Symptomatic Hyperprolactinemia by Aripiprazole
Wahl, R., & Ostroff, R. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1542-a · Cited by 45
Assays for Prolactin: Guidelines for the Provision of a Clinical Biochemistry Service
Jeffcoate, S. L., Bacon, R. R. A., Beastall, G. H., Diver, M. J., Franks, S., & Seth, J. (1986) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456328602300603 · Cited by 44
Aripiprazole in Children and Adolescents: Clinical Experience
Rugino, T. A., & Janvier, Y. M. (2005) · Journal of Child Neurology · doi:10.1177/08830738050200071301 · Cited by 43
Hyperprolactinaemia in Antipsychotic-Treated Patients
Hamner, M. B., & Arana, G. W. (1998) · CNS Drugs · doi:10.2165/00023210-199810030-00005 · Cited by 42
A new atypical antipsychotic: quetiapine-induced sexual dysfunctions
Atmaca, M., Kuloğlu, M. M., & Tezcan, E. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901260 · Cited by 42
Serum Haloperidol Determinations in Psychiatric Patients
Rubín, R. T. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780220107012 · Cited by 42
Poland, R. E., & Rubín, R. T. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90514-2 · Cited by 41
Adverse effects of risperidone and haloperidol treatment in schizophrenia
Yen, Y., Lung, F., & Chong, M. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.006 · Cited by 41
Harvey, P. W., Everett, D. J., & Springall, C. (2006) · Human & Experimental Toxicology · doi:10.1191/0960327106ht643oa · Cited by 40
Hellings, J. A., Zarcone, J. R., Valdovinos, M. G., Reese, R. M., Gaughan, E. T., & Schroeder, S. R. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.885 · Cited by 38
Risperidone-induced Symptomatic Hyperprolactinaemia in Adolescents
Holzer, L., & Eap, C. B. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203194.58087.9a · Cited by 38
Management Options for Bipolar Disorder in Children and Adolescents
Danielyan, A., & Kowatch, R. A. (2005) · Pediatric Drugs · doi:10.2165/00148581-200507050-00002 · Cited by 34
A pilot study of a structured interview addressing sexual function in men with schizophrenia
Burke, M. A., McEvoy, J. P., & Ritchie, J. C. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91164-9 · Cited by 34
Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine?
Smith, S. L. (1992) · PubMed · Cited by 32
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Naber, D., Fischer, H., & Ackenheil, M. (1979) · PubMed · Cited by 32
Long-term effects of neuroleptic drugs on the neuroendocrine system.
Hy, M. (1985) · PubMed · Cited by 31
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia
Buckley, P. F., Goldstein, J. M., & Emsley, R. A. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.06.001 · Cited by 31
Atypical Experience: A Case Series of Pediatric Aripiprazole Exposures
Lofton, A., & Klein‐Schwartz, W. (2005) · Clinical Toxicology · doi:10.1081/clt-53095 · Cited by 30
The Behavioral Toxicity of Bromocriptine in Patients with Psychiatric Illness
Perovich, R., Lieberman, J. A., Fleischhacker, W. W., & Alvir, J. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198912000-00006 · Cited by 30
Serum Prolactin as a Correlate of Clinical Response to
Putten, T. V., Marder, S. R., & Mintz, J. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199112000-00005 · Cited by 29
Patients' opinions concerning side effects of depot neuroleptics
Buis, W. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.6.844a · Cited by 29
Galactorrhea: subjective response by schizophrenic patients
Wesselmann, U., & Windgassen, K. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09758.x · Cited by 28
Successful Switch to Aripiprazole After Induction of Hyperprolactinemia by Ziprasidone
Anghelescu, I. G., & Wolf, J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0918f · Cited by 27
Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports
Haddad, P. M., Hellewell, J. S. E., & Wieck, A. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500408 · Cited by 26
Csernansky, J. G., Prosser, E. S., Kaplan, J., Mahler, E., Berger, P. A., & Hollister, L. E. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90124-1 · Cited by 25
High-Dose Olanzapine and Prolactin Levels
Karagianis, J. L., & Baksh, A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1008 · Cited by 24
Spotlight on Ziprasidone in Schizophrenia and Schizoaffective Disorder*
Gunasekara, N. S., Spencer, C. M., & Keating, G. M. (2002) · CNS Drugs · doi:10.2165/00023210-200216090-00005 · Cited by 23
The Effects of Antipsychotic Drug Treatment on Prolactin Concentrations in Elderly Patients
Kinon, B. J., Stauffer, V. L., McGuire, H. C., Kaiser, C. J., Dickson, R. A., & Kennedy, J. S. (2003) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70344-8 · Cited by 23
Meltzer, H. Y., & Busch, D. A. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90002-1 · Cited by 22
de León, J., DÍAZ, F. J., Josiassen, R. C., & Simpson, G. M. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0505-2 · Cited by 21
Osteoporosis associated with neuroleptic treatment. A case report.
Kartaginer, J., Ataya, K. M., Mercado, A., & Abbasi, A. A. (1990) · PubMed · Cited by 19
Lack of tolerance to long‐term neuroleptic treatment in dopamine tuberoinfundibular system
Chouinard, G., Annable, L., Jones, B., & COLLU, R. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00794.x · Cited by 18
High plasma prolactin levels after long-term neuroleptic treatment
Zelaschi, N. M., Delucchi, G. A., & Rodríguez, J. L. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00589-7 · Cited by 15
A study on serum prolactin levels in schizophrenia
Kuruvilla, A., Srikrishna, G., Peedicayil, J., Kuruvilla, K., & Kanagasabapathy, A. S. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00007 · Cited by 14
Progressive Trabecular Osteopenia in Women With Hyperprolactinemic Amenorrhea
Biller, B. M. K., Baum, H. B. A., Rosenthal, D. I., SAXE, V. C., Charpie, P. M., & Klibanski, A. (1993) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199302000-00025 · Cited by 14
Prolactin Elevation With Ziprasidone
Lusskin, S. I., Cancro, R., CHUANG, L., & JACOBSON, J. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1925 · Cited by 13
Aripiprazole in the Treatment of Bipolar Disorder in Children and Adolescents
Durkin, J. P. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.505 · Cited by 11
Prolactin response to single and multiple doses of haloperidol in schizophrenic patients
Ravichandran, G., Lu, R., Shvartsburd, A., Misra, C. H., Ho, B. T., Kahn, M., & Smith, R. C. (1984) · Psychiatry Research · doi:10.1016/0165-1781(84)90108-2 · Cited by 10
Copolov, D., Keks, N. A., Kulkarni, J., SINGH, B. S., McKenzie, D. P., McGorry, P. D., & Hill, C. (1990) · Psychoneuroendocrinology · doi:10.1016/0306-4530(90)90033-6 · Cited by 9
Kaneda, Y., & Fujii, A. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00378.x · Cited by 9
Bone mineral density in premenopausal women with antipsychotic-induced hyperprolactinaemia
Akande, B., Wieck, A., & Haddad, P. M. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80462-x · Cited by 5
Management of Hyperprolactinemia in Patients Receiving Antipsychotics
Seftel, A. D. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(05)61077-4 · Cited by 3
Seftel, A. D. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000155176.16668.1c · Cited by 1
Research works printed but not linked: 3
- Cook, 1992, Pediatric reference ranges for prolactin., Clin Chem, 38, 959
- Kaneda, 2000, Neither gynaecomastia nor galactorrhea is a common side effect of neuroleptics in male patients., Neuroendocrinol Lett, 21, 447
- Ansbacher, 1990, Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting., Obstet Gynecol, 76, 895
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Sex differences in the psychopharmacological treatment of depression
Sramek, J. J., Murphy, M. F., & Cutler, N. R. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/ncutler · Cited by 341
Metadata
- Authors
- Byerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Otsuka (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Byerly, Matthew
- Suppes, Trisha
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-12
- Volume
- 27
- Issue
- 6
- Pages
- 639-661
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1965091910
- Cited by
- 153
- References
- 184
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 10 · 2016: 10 · 2015: 11 · 2014: 11 · 2013: 10 · 2012: 9
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- antipsychotic-induced hyperprolactinemia, schizophrenia spectrum disorders, bipolar spectrum disorders, typical antipsychotics, atypical antipsychotics, risperidone, paliperidone, galactorrhea, gynecomastia, sexual dysfunction, reproductive disorders, carcinogenesis, osteoporosis, medication adherence, long-term health risks
- MeSH terms
- Bipolar Disorder, Humans, Hyperprolactinemia, Models, Biological, Psychopharmacology, Schizophrenia, Antipsychotic Agents, Meta-Analysis as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review